eavesdropping in Houston

Overheard: Space experts discuss commercialization, innovation, and Houston's future

What's Houston's role in the modern era for aerospace? And how can the industry foster public-private collaboration? Experts weighed in at a recent event. Photo via NASA

The aerospace industry — much more than other sectors — is run by a mixture of civil, commercial, and military players. And each of these verticals operate very differently.

At a Houston Tech Rodeo event called "Lasso the Moon" put on by Space Force Association and TexSpace, aerospace experts representing various entities — from startups to big tech to education and military organizations — discussed the future of space innovation.

Missed the conversation? Here are five key moments from the event, which included several talks and a panel at The Ion on Monday, February 28.

 "In this age of rapid advancement, Houston has to take an active stance on supporting space innovation. Leaders must leverage all that this great city and our community have to offer, and we must align civil, commercial, and academic communities to work together to build an effective space innovation ecosystem."

— Mayor Sylvester Turner says at the event's welcome address. “Ever since Houston was the first said from the surface of the moon, Houston has been known as the Space City," he says.

“How is the tech industry going so fast in updating their technology, but the government is struggling? … The system is not designed to innovate.”

— United States Space Force Lt. Gen. Chance Saltzman says, addressing innovation in space and war operations. He adds, "The system is designed to just do continuous improvement on existing capability. When we talk about the need to shift or jump and revolutionize the technology we are using, there are a lot of things at play working against us."

“Houston is the global energy capital, human spaceflight capital of the world, and has the biggest medical center of the world. All of these sectors are heavily dependent on innovation and technology. And many of these technologies overlap. It’s time to switch to technology verticals.”

— David Alexander, professor in the department of physics and astronomy at Rice University, says in a call for industries in Houston to work together. "If you focus on the technologies, then collaboration happens."

"Houston intimately understands innovation. We come from a city of wildcatters."

— Sarah Duggleby, CEO and cofounder of Venus Aerospace, says in her talk about how she's growing her California-founded company in its new Houston headquarters. She added that Texas makes it "infinitely easier to do business."

"Innovation in our business usually equates to risk. Usually when we start to on a project, we like to use time-proven technologies. Creating onramps for technology and innovation has to be something that we plan."

— Sam Gunderson, lead of partnership development at NASA's Johnson Space Center, says adding: "The other thing that I think creates a challenge for innovation within industry that I think the government needs to improve on is that we often over-define our solution set when we try to (onboard new technology). Leaving room for innovation and for people to bring something in that doesn't solve the problem in the way we anticipated needs to be a part of the way we buy services."

"You're a private business — you're trying to grow, you're trying to scale, you need cash. The government has a lot of it. It's perfectly aligned – if you do it right." 

​— Enrique Oti, CTO at Second Front Systems, says on the process of getting grants and submitting RFPs within government agencies. "There are lots of way to do it, but the only way you can get there as a startup or small company is if you're blatantly asking for the money and information."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted